Abstracts tagged "Sjogren’s syndrome and autoantibodies"

Abstract Number: 559 • 2017 ACR/ARHP Annual Meeting
Performance of Multiple Platforms for Autoantibody Testing in Sjogren’s Syndrome
Astrid Rasmussen¹, Kiely Grundahl², Lida Radfar³, C. Erick Kaufman⁴, David M. Lewis⁵, Barbara M. Segal⁶, Nelson L. Rhodus⁷, Harini Bagavant¹, Umesh Deshmukh⁸, Christopher J Lessard⁸, R. Hal Scofield¹ and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁴College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Department of Oral Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁶Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ⁷Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The research classification and clinical diagnosis of SjšgrenÕs syndrome (SS) relies heavily on the detection of autoantibodies against Ro/SSA and La/SSB, particularly in the…
Abstract Number: 564 • 2017 ACR/ARHP Annual Meeting
Molecular Identification of a Ro-Specific Salivary IgA Repertoire with Unique Clonal Signatures in Primary Sjogren’s Syndrome
Jing Jing Wang¹, Alexander Colella¹, Tim Chataway², R. Hal Scofield³ and Tom Gordon^1,4, ¹Immunology, Flinders University, Adelaide, Australia, ²Proteomic Facility, Flinders University, Adelaide, Australia, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Autoantibodies against 60-kD Ro (Ro60)/SSA have been detected in the saliva and serum of patients with primary Sjögren's syndrome (SS) by routine methods that…
Abstract Number: 571 • 2017 ACR/ARHP Annual Meeting
Anti-Modified Protein Antibody Response Pattern in Primary Sjögren’s Syndrome: Clinical and Prognostic Implications
Alessia Alunno¹, Francesco Carubbi^2,3, Holger Bang⁴, Onelia Bistoni¹, Paul Studenic⁵, Günter Steiner⁵, Elena Bartoloni⁶, Josef S. Smolen^5,7 and Roberto Gerli¹, ¹Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ²ASL1 Avezzano L'Aquila Sulmona, L'Aquila, Italy, ³Rheumatology Unit, University of L'Aquila, L'Aquila, Italy, ⁴Orgentec Diagnostika GmbH, Mainz, Germany, ⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁶Rheumatology Unit, University of Perugia, Perugia, Italy, ⁷Hietzing Hospital, Department of Internal Medicine, Vienna, Austria
Background/Purpose: Over the last decades, several post translationally modified proteins have been identified as auto-antigens in rheumatoid arthritis (RA). No data regarding Abs against acetylated…
Abstract Number: 2802 • 2015 ACR/ARHP Annual Meeting
Co-Occurence of Anti-Ro52/TRIM21 and Anti-TRIM38 Autoantibodies Is Associated with Higher Severity of Dry Eye in Sjögren’s Syndrome
Nina Wolska¹, Paulina Rybakowska¹, Arkadiusz Klopocki¹, Michael Brown¹, Courtney G. Montgomery², Kiely Grundahl¹, Astrid Rasmussen¹, Robert Hal Scofield³, Lida Radfar⁴, Donald U Stone⁵, Juan-Manuel Anaya^6,7, John Ice², Christopher Lessard³, David M. Lewis⁸, Nelson L. Rhodus⁹, Raj Gopalakrishnan¹⁰, Andrew Huang¹¹, Pamela J Hughes¹², Michael D. Rohrer¹³, Michael Weismann¹⁴, Swamy Venuturupalli¹⁵, Joel M. Guthridge³, Judith A. James¹⁶, Kathy L. Sivils³, Harini Bagavant¹⁷, Umesh S Deshmukh¹⁷ and , ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Dean McGee Eye Institute, Oklahoma City, OK, ⁶Rheumatology, Center for Autoimmune Diseases Research (CREA), Rosario University, Bogotá, Colombia, ⁷Cell Biol and Immunogenetics, CIB-Rosario University, Medellin, Colombia, ⁸College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁰Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹¹Washington University,, St Louis, MO, ¹²Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹³Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁴Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁵Cedars-Sinai Medical Center, West Hollywood, CA, ¹⁶Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Autoantibodies reactive with Ro52/TRIM21 are detected in almost 70% of primary Sjögren’s syndrome (pSjS) patients and their presence is associated with higher severity of…
Abstract Number: 2542 • 2014 ACR/ARHP Annual Meeting
La Positive, Ro60 Negative Subset of Primary Sjögren’s Syndrome Is a Reality
Debashish Danda¹, Dat Truong², Marshall Shaw³, Celia Quang³, Kristi A. Koelsch⁴, Biji T. Kurien⁵, Harini Bagavant², Umesh Deshmukh² and R. Hal Scofield⁶, ¹Clincial Immunology and Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ⁵U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁶US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose Twenty-nine sera from 348 primary Sjögren’s syndrome patients were identified as anti-Ro60 (anti-SSA) negative and anti-La (anti-SSB) positive by immunodiffusion, line immunoassays and multiplex…
Abstract Number: 2200 • 2012 ACR/ARHP Annual Meeting
IgE Autoantibodies Against SSA and SSB in Patients with Sjögren’s Syndrome and Healthy Controls
Stamatina Danielides¹, Barbara Dema², Juan Rivera² and Gabor G. Illei³, ¹Nidcr, NIH, Bethesda, MD, ²Laboratory of Molecular Immunogenetics, NIAMS, NIH, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disorder, presenting as an autoimmune exocrinopathy. Although the pathogenesis of this disease is largely unknown, evidence indicates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].